tiprankstipranks
Advertisement
Advertisement

MNPR Stock Latest News

Monopar: Buy Rating Reiterated as ALXN1840 Data Underpin Valuation and $104 Price Target Maintained
RatingsMonopar: Buy Rating Reiterated as ALXN1840 Data Underpin Valuation and $104 Price Target Maintained
14d ago
MNPR
Monopar Therapeutics presents ALXN1840-WD-205 data at EASL
PremiumThe Fly
Monopar Therapeutics presents ALXN1840-WD-205 data at EASL
15d ago
MNPR
Monopar Highlights Phase 2 ALXN1840 Data in Wilson Disease
PremiumCompany Announcements
Monopar Highlights Phase 2 ALXN1840 Data in Wilson Disease
17d ago
8K
MNPR
Monopar Showcases ALXN1840 Phase 2 Wilson Disease Data
PremiumCompany Announcements
Monopar Showcases ALXN1840 Phase 2 Wilson Disease Data
27d ago
8K
MNPR
Monopar Buy Rating Reiterated on Advancing ALXN1840 Profile and De-Risked Regulatory Path; $104 Price Target Unchanged
PremiumRatings
Monopar Buy Rating Reiterated on Advancing ALXN1840 Profile and De-Risked Regulatory Path; $104 Price Target Unchanged
1M ago
MNPR
Monopar Highlights Strong Phase 3 Data for ALXN1840
PremiumCompany AnnouncementsMonopar Highlights Strong Phase 3 Data for ALXN1840
2M ago
8K
MNPR
ALXN1840 Poised to Redefine Wilson Disease Treatment Standards: Phase 3 Success, De-Risked Profile, and Buy Rating Justification
Premium
Ratings
ALXN1840 Poised to Redefine Wilson Disease Treatment Standards: Phase 3 Success, De-Risked Profile, and Buy Rating Justification
2M ago
MNPR
Monopar announces new analyses from Phase 3 FoCus trial of ALXN1840
Premium
The Fly
Monopar announces new analyses from Phase 3 FoCus trial of ALXN1840
2M ago
MNPR
Buy Rating Reaffirmed on ALXN1840 De‑Risking, 2027 Approval Potential, and Strong Cash Runway
PremiumRatings
Buy Rating Reaffirmed on ALXN1840 De‑Risking, 2027 Approval Potential, and Strong Cash Runway
3M ago
MNPR
MNPR Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
MNPR Upcoming Earnings Report: What to Expect?
3M ago
MNPR
Monopar Appoints Chief Commercial and Strategy Officer Rodriguez
PremiumCompany Announcements
Monopar Appoints Chief Commercial and Strategy Officer Rodriguez
4M ago
8K
MNPR
Monopar Therapeutics appoints Susan Rodriguez as CCSO
PremiumThe Fly
Monopar Therapeutics appoints Susan Rodriguez as CCSO
4M ago
MNPR
MNPR: Favorable Risk/Reward on ALXN1840’s Differentiated Profile and De-Risked Regulatory Pathway in Wilson’s Disease
PremiumRatingsMNPR: Favorable Risk/Reward on ALXN1840’s Differentiated Profile and De-Risked Regulatory Pathway in Wilson’s Disease
4M ago
MNPR
3 Best Stocks to Buy Today, 1/30/2026, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Today, 1/30/2026, According to Top Analysts
5M ago
ENGN
MNPR
3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts
Premium
Market News
3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts
5M ago
CYTK
MNPR
Monopar Therapeutics initiated with an Overweight at Morgan Stanley
PremiumThe Fly
Monopar Therapeutics initiated with an Overweight at Morgan Stanley
5M ago
MNPR
Monopar Therapeutics: ALXN1840’s Differentiated Efficacy, De‑Risked Profile, and Strong Cash Runway Underpin Overweight/Buy Rating
PremiumRatings
Monopar Therapeutics: ALXN1840’s Differentiated Efficacy, De‑Risked Profile, and Strong Cash Runway Underpin Overweight/Buy Rating
5M ago
MNPR
Optimistic Buy Rating for Monopar Therapeutics Inc: Promising ALXN1840 Data and Strong Financial Position
PremiumRatings
Optimistic Buy Rating for Monopar Therapeutics Inc: Promising ALXN1840 Data and Strong Financial Position
7M ago
MNPR
Monopar downgraded to Outperform from Strong Buy at Raymond James
PremiumThe Fly
Monopar downgraded to Outperform from Strong Buy at Raymond James
7M ago
MNPR
Monopar Therapeutics Reports Increased Cash Reserves Amid Losses
PremiumCompany AnnouncementsMonopar Therapeutics Reports Increased Cash Reserves Amid Losses
7M ago
MNPR
Monopar Therapeutics reports Q EPS (48c), consensus (40c)
Premium
The Fly
Monopar Therapeutics reports Q EPS (48c), consensus (40c)
7M ago
MNPR
Promising Potential of Monopar Therapeutics: Buy Rating Backed by ALXN1840’s Efficacy and Safety Data
Premium
Ratings
Promising Potential of Monopar Therapeutics: Buy Rating Backed by ALXN1840’s Efficacy and Safety Data
7M ago
MNPR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >